APOE and hyperlipidemia: Moreover, systemic genetic ablation of ACKR3 was shown to cause hyperlipidemia in Apolipoprotein E deficient (Apoe−/−) mice, whereas its activation through CCX771 injections in mice decreased serum cholesterol and triglyceride levels [13].